MyVisionTest News Archive
Displaying news items tagged with histoplasmosis (More tags »)SELECT PAGE
First << 1 >> Last
First << 1 >> Last

Aug 24, 2010
The clinical characteristics of a large series of patients with punctate inner choroidopathy (PIC) is presented in a new research report. The term punctate inner choroidopathy (PIC) was first used by Watzke et al in 1984 to describe findings in a group of 10 patients with multifocal, well-circumscribed, usually small choroidal lesions. These...
Nov 26, 2009
Intravitreal Avastin (bevacizumab) is effective in the treatment of choroidal neovascularization (CNV) resulting from presumed ocular histoplasmosis syndrome, according to a new study. Histoplasmosis is a disease caused when airborne spores of the fungus Histoplasma capsulatum are inhaled in the lungs. Histoplasmosis is sometimes so mild that...Tags: Avastin, histoplasmosis

Oct 19, 2009
The Berkshire Priorities Committee, which advises the National Health Service (NHS) of the United Kingdom (UK) on health care interventions and policies, has issued a "Low Priority" funding directive for anti-VEGF therapy for ocular neovascularization from conditions other than age-related macular degeneration (AMD), including ocular...
Jun 15, 2009
A new study finds that combined anti-VEGF and photodynamic therapy (PDT) is effective for juxtafoveal and extrafoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), ocular histoplasmosis syndrome (OHS), and degenerative myopia. Laser photocoagulation is the standard therapy for CNV that occurs outside the...Tags: Avastin, photodynamic therapy, wet AMD, myopia, histoplasmosis, Lucentis, laser photocoagulation

Jan 13, 2009
The anti-VEGF drugs Lucentis and Avastin are effective in the treatment of choroidal neovascularization (CNV) secondary to multifocal choroiditis, according to a new research report. Multifocal choroiditis (MFC) is an inflammatory condition, occasionally associated with choroidal neovascularization (CNV). Some cases of MFC are believed to be...
Jul 15, 2008
A new study finds that CNV secondary to non-AMD causes treated with Avastin responded favorably and similarly, despite varying underlying etiologies. The investigators performed a retrospective analysis of eyes that received intravitreous Avastin (bevacizumab, 1.25 mg), for subfoveal non-AMD CNV at a referral-based retinal practice. Repeated...SELECT PAGE
First << 1 >> Last
First << 1 >> Last